Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma In Situ

摘要

ObjectiveIn the absence of consistent guidelines for the use of adjuvant hormonal therapy (HT) in treating ductal carcinoma in situ (DCIS), our purpose was to explore a variety of factors associated with discussion, use, and discontinuation of this therapy for DCIS, including patient, tumor, and treatment-related characteristics and physician-patient communication factors.